8-K: Calavo Growers Reports Mixed Q3 2025 Results, Prepared Segment Soars

Calavo Growers, Inc. announced its third quarter and nine-month financial results, showing strong growth in its Prepared segment despite a temporary FDA detention hold impacting Fresh segment profitability.

Summary

• Total net sales for the third quarter ended July 31, 2025, were $178.8 million, a decrease of less than one percent from the prior year.
• Fresh segment sales decreased by 5% to $155.9 million, primarily due to an 8% decrease in cartons sold, including lower avocado and tomato volumes.
• Prepared segment sales increased by 40% to $22.9 million, driven by a 35% increase in sales volume.
• Gross profit for the third quarter was $18.2 million, a 9% decrease, and included approximately $4.2 million in discrete costs related to a temporary FDA detention hold on certain avocado imports from Mexico.
• Net income from continuing operations attributable to Calavo Growers, Inc. was $4.7 million, or $0.26 per diluted share, compared to $5.4 million, or $0.30 per diluted share, in the prior year quarter.
• Adjusted net income increased to $10.2 million, or $0.57 per diluted share, compared to $10.0 million, or $0.56 per diluted share, in the prior year.
• Adjusted EBITDA was $15.1 million, up from $12.9 million in the prior year quarter.
• For the nine-month period, total net sales increased 7% to $523.8 million, with Fresh segment sales up 6% and Prepared segment sales up 10%.
• Nine-month net income from continuing operations was $16.1 million, or $0.89 per diluted share, compared to $9.3 million, or $0.52 per diluted share, in the prior year period.
• The U.S. Department of Justice officially closed its Foreign Corrupt Practices Act (FCPA) inquiry related to operations in Mexico on September 2, 2025.
• The temporary FDA detention hold on avocado imports was resolved as of September 2, 2025, and is believed to be a non-recurring event.
• A Federal Court in Mexico formally recognized Calavo de Mexico as a maquila, which is expected to strengthen the position to recover value-added tax (IVA) receivables and bolster defense in a 2013 assessment.

Sentiment

Score: 7

Explanation: The sentiment is cautiously positive. While GAAP net income for the quarter declined due to a significant one-time event (FDA hold), the adjusted financial metrics show improvement. The resolution of the FDA hold and the FCPA inquiry removes major uncertainties. The Prepared segment's strong growth and positive outlook are significant drivers of optimism, offsetting the challenges in the Fresh segment.

Positives

• Prepared segment sales increased by 40% to $22.9 million in Q3 2025, driven by a 35% increase in sales volume, reflecting strong demand and scaling programs.
• Prepared segment gross profit surged by 201% to $5.8 million in Q3 2025, primarily due to improved operational efficiency and stronger cost management.
• Selling, general, and administrative (SG&A) expenses decreased by 12% to $9.2 million in Q3 2025, mainly due to lower professional and consulting fees, including reduced FCPA investigation-related legal expenses.
• Adjusted net income for Q3 2025 increased to $10.2 million, or $0.57 per diluted share, compared to $10.0 million, or $0.56 per diluted share, in the prior year.
• Adjusted EBITDA for Q3 2025 increased to $15.1 million, compared to $12.9 million in the prior year.
• The U.S. Department of Justice officially closed its FCPA inquiry related to operations in Mexico on September 2, 2025, removing a significant legal overhang.
• The temporary FDA detention hold on avocado imports was resolved as of September 2, 2025, and is considered a non-recurring event, mitigating future similar disruptions.
• A Federal Court in Mexico formally recognized Calavo de Mexico as a maquila, which is expected to strengthen the position to recover IVA receivables and bolster defense in a 2013 assessment.
• Strong liquidity position with $63.8 million in cash and cash equivalents and $114.3 million in available liquidity as of July 31, 2025, with no borrowings under the revolving credit facility.

Negatives

• Total net sales for Q3 2025 decreased by less than one percent to $178.8 million.
• Fresh segment sales decreased by 5% to $155.9 million in Q3 2025, reflecting an 8% decrease in overall cartons sold, including lower avocado (down 5%) and tomato (down 27%) volumes.
• Gross profit for Q3 2025 decreased by 9% to $18.2 million, significantly impacted by approximately $4.2 million of discrete costs associated with a temporary FDA detention hold on certain avocado imports from Mexico.
• Fresh segment gross profit decreased by 32% to $12.4 million in Q3 2025, primarily due to lower avocado volumes and the FDA detention hold costs.
• Net income from continuing operations attributable to Calavo Growers, Inc. for Q3 2025 decreased to $4.7 million, or $0.26 per diluted share, compared to $5.4 million, or $0.30 per diluted share, in the prior year.
• Third quarter avocado selling prices were significantly lower sequentially versus the second quarter due to converging supply from Mexico, California, and Peru.
• Tomato performance was pressured by adverse weather and abundant domestic supply, which reduced import demand and compressed margins.

Risks

• Impact of weather on market conditions and seasonality of the business.
• Sensitivity of the business to changes in market prices of avocados and other agricultural products, as well as raw materials like fuel, packaging, and paper.
• Changes or actions associated with USDA-APHIS and Mexican Secretary of Agriculture phytosanitary regulations.
• Potential disruptions to the supply chain.
• Risks associated with potential future acquisitions, including integration challenges.
• Potential exposure to data breaches and other cyber-attacks on systems or those of suppliers or customers.
• Dependence on large customers and key personnel, as well as access to necessary labor.
• Susceptibility to wage inflation and potential for labor disputes.
• Reliance on co-packers for a portion of production needs.
• Competitive pressures, including from foreign growers.
• Risks of recalls and food-related injuries to customers.
• Changing consumer preferences.
• Impact of environmental regulations, including those related to climate change, especially as they may affect sources of supply.
• Risks associated with doing business internationally, including possible non-compliance with U.S. and foreign laws, restrictive governmental actions (e.g., trade protection measures, restrictions on fund transfers), and currency fluctuations.
• Risks associated with receivables from, loans to, and/or equity investments in unconsolidated entities.
• Volatility in the value of common stock.
• Impact of macroeconomic trends and events, and the effects of increased interest rates on borrowing costs and consumer purchasing behavior.
• The resolution of pending internal and external investigations, legal claims, and tax disputes, including an assessment imposed by the Mexican Tax Administrative Service (SAT) and defenses against collection activities.
• Ability to realize expected expense savings from the sale of the Fresh Cut business.
• Risks related to enhanced regulatory scrutiny or inspection protocols, including detention holds by the FDA, which can result in shipment delays, third-party testing requirements, incremental logistics and handling costs, and inventory write-downs, and could in the future result in additional delays, costs, loss of product value, and disruption to customer orders.

Future Outlook

Management projects Prepared segment sales of approximately $115 million for fiscal 2026, indicating continued strong growth in this area. The temporary FDA detention hold is believed to be a non-recurring event, suggesting a more stable Fresh segment performance moving forward. The company also anticipates strengthening its position to recover IVA receivables and bolstering its defense in the 2013 assessment following the maquila recognition.

Management Comments

• "Our third quarter results highlight both the challenges and the opportunities in our business," said Lee Cole, President and Chief Executive Officer of Calavo Growers, Inc.
• Cole noted that Fresh segment results were adversely affected by the temporary FDA detention hold tied to trace detection of Imazalil and significantly lower avocado selling prices sequentially versus the second quarter due to converging supply.
• "In contrast, our Prepared segment delivered outstanding growth with higher volumes," Cole stated.
• "As of September 2, 2025, the FDA matter has been resolved. This was the first detention hold in the history of Calavo de Mexico since operations began in 1998, and we believe it was a non-recurring event," Cole continued.
• Cole highlighted achieving an important legal milestone in August, with a Federal Court in Mexico formally recognizing Calavo de Mexico as a maquila, which strengthens the position to recover IVA receivables and bolsters defense in the 2013 assessment.
• "Combined with the momentum in our Prepared segment, where July sales, on a monthly run-rate basis, annualize to over $100 million and where we currently project Prepared segment sales of approximately $115 million for fiscal 2026, I believe Calavo is well positioned for growth and increased shareholder value," Cole concluded.

Industry Context

The Fresh segment faced challenges from converging avocado supply from Mexico, California, and Peru, leading to significantly lower selling prices. Additionally, tomato performance was pressured by adverse weather conditions and abundant domestic supply, which limited import opportunities and compressed margins. These factors reflect the inherent volatility and sensitivity of the fresh produce industry to supply-demand dynamics and environmental conditions. In contrast, the Prepared segment's strong volume growth and improved efficiencies suggest a successful adaptation to consumer demand for value-added avocado products.

Corporate Governance

Legal Proceedings

• The U.S. Department of Justice officially closed its Foreign Corrupt Practices Act (FCPA) inquiry related to operations in Mexico on September 2, 2025.
• A Federal Court in Mexico formally recognized Calavo de Mexico as a maquila, which is expected to strengthen the company's position to recover value-added tax (IVA) receivables and bolster its defense in the 2013 assessment by the Mexican Tax Administrative Service (SAT).

Stakeholder Impact

• Shareholders: Will receive a quarterly cash dividend of $0.20 per share. The resolution of legal and regulatory issues and strong adjusted performance could positively influence share price and long-term value.
• Customers: Experienced temporary disruptions and delays in avocado supply due to the FDA detention hold, though the issue is now resolved. Strong Prepared segment growth indicates consistent product availability in that category.
• Employees: Experienced a reduction in compensation expenses reflecting lower headcount and severance costs in the nine-month period, though bonus expense increased in Q3.
• Suppliers: Impacted by the FDA detention hold on avocado imports from Mexico, leading to inventory write-downs and distressed sales for some fruit.

Next Steps

• Continue efforts to recover value-added tax (IVA) receivables in Mexico.
• Bolster defense in the 2013 assessment by the Mexican Tax Administrative Service (SAT).
• Pursue recovery from the insurance company for costs related to the FDA detention hold.
• Focus on continued growth and operational efficiency in the Prepared segment, with projected sales of approximately $115 million for fiscal 2026.

Key Dates

Recommendation

A 'Buy' recommendation is warranted for a seasoned investor. While Q3 GAAP net income saw a temporary dip, this was primarily due to a one-time, resolved FDA detention hold. The underlying business, particularly the Prepared segment, is demonstrating robust growth (40% sales increase, 201% gross profit increase in Q3) and has a strong fiscal 2026 outlook. Crucially, significant legal and regulatory overhangs, including the FCPA inquiry and the FDA issue, have been resolved, removing major uncertainties. Adjusted financial metrics show healthy improvement, and the company maintains strong liquidity. These factors suggest a positive trajectory once the temporary Fresh segment headwinds subside, making it an attractive entry point for long-term growth.

Keywords

Calavo Growers, CVGW, Q3 2025 earnings, financial results, avocado, guacamole, fresh produce, FDA detention, FCPA inquiry, Mexico operations, Prepared segment, Fresh segment, adjusted EBITDA, corporate governance, agricultural products